Glucose metabolic reprogramming in autoimmune diseases

Autoimmune diseases are conditions in which the immune system mistakenly targets and damages healthy tissue in the body. In recent decades, the incidence of autoimmune diseases has increased, resulting in a significant disease burden. The current autoimmune therapies focus on targeting inflammation...

Full description

Saved in:
Bibliographic Details
Published in:Animal cells and systems 2023, 27(1), , pp.149-158
Main Authors: Jeong, Hoim, Lee, Beomgu, Han, Seung Jin, Sohn, Dong Hyun
Format: Article
Language:English
Subjects:
Autoimmune diseases
Chronic conditions
Diabetes
Diabetes mellitus (insulin dependent)
Disease
Energy
Enzymes
Glucose
Glucose metabolic reprogramming
glucose transporter
glycolysis
Immune system
Immunology
Immunosuppression
Lupus
Lymphocytes
Metabolic pathways
Metabolism
Metabolites
metformin
Multiple sclerosis
Oxidative stress
Phosphorylation
Review
Rheumatoid arthritis
Systemic lupus erythematosus
Systemic sclerosis
생물학
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Autoimmune diseases are conditions in which the immune system mistakenly targets and damages healthy tissue in the body. In recent decades, the incidence of autoimmune diseases has increased, resulting in a significant disease burden. The current autoimmune therapies focus on targeting inflammation or inducing immunosuppression rather than addressing the underlying cause of the diseases. The activity of metabolic pathways is elevated in autoimmune diseases, and metabolic changes are increasingly recognized as important pathogenic processes underlying these. Therefore, metabolically targeted therapies may represent an important strategy for treating autoimmune diseases. This review provides a comprehensive overview of the evidence surrounding glucose metabolic reprogramming and its potential applications in drug discovery and development for autoimmune diseases, such as type 1 diabetes, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, and systemic sclerosis.
ISSN:1976-8354
2151-2485
DOI:10.1080/19768354.2023.2234986